Reports Q3 revenue $51.5M, consensus $50.7M.”We delivered solid year-over-year revenue growth in the third quarter of 2024 despite persistent industry headwinds, demonstrating how we are leading with the strength of our portfolio, loyal customer base and reputation in serving growing markets that need better technology for cell analysis,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences (CTKB). “As we look ahead, we remain focused on strong execution of our growth pillars and building on the positive momentum we are seeing with the demand for our products. With the combination of our industry-leading end-to-end technology portfolio, global diversification and clear long-term growth drivers, we believe we are fundamentally well positioned to deliver sustainable growth and profitability.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTKB:
- CTKB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cytek Biosciences announces resignation of Chief Operating Officer
- Cytek Biosciences COO Resigns, Signaling Leadership Changes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
